Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy.
Chinese-herb nephropathy (CHN) is a progressive renal interstitial fibrosis initially reported after concomitant intake of an anorexigen, (dex)fenfluramine, and a Chinese herb ( Aristolochia fangchi) containing nephrotoxic and carcinogenic aristolochic acid (AA). We thus tested the possible enhancing effect of the active enantiomer dexfenfluramine (DXF) on AA nephrotoxicity in a rat model for CHN. Groups of 12 salt-depleted male Wistar rats received daily subcutaneous injections of 7 mg/kg body weight DXF (DXF group), 7 mg/kg body weight AA (AA group), a combination of the same doses of AA and DXF (AA+DXF group), or vehicle (control group) for up to 35 days. Six animals per group were killed on day 10 and the remaining six on day 35. Renal function was evaluated by determining serum creatinine and urinary leucine aminopeptidase activity. Histological evaluation of kidney samples was performed and tubulointerstitial injuries were semiquantified. The DXF group did not differ from controls for any parameter. Similarly elevated serum creatinine levels, decreased leucine aminopeptidase enzymuria, and renal lesions were observed in the AA and the AA+DXF groups after both 10 and 35 days. The formation of specific AA-DNA adducts in liver and renal tissue samples was assessed by the (32)P-postlabelling method. Specific AA-DNA adduct levels were significantly increased in kidney tissues from AA+DXF rats compared with AA rats. These functional and histological data suggest that DXF does not enhance AA nephrotoxicity in a rat model for CHN. Further investigations are needed to clarify the mechanism by which DXF may enhance AA-DNA adduct formation.
Debelle
Frédéric
F
Laboratoire de Recherche sur le Métabolisme des Peptides (L.R.M.P.), Faculté de Médecine, Université Libre de Bruxelles, 1070, Brussels, Belgium.
Nortier
Joëlle
J
Arlt
Volker M
VM
De Prez
Eric
E
Vienne
Anne
A
Salmon
Isabelle
I
Phillips
David H
DH
Deschodt-Lanckman
Monique
M
Vanherweghem
Jean-Louis
JL
D000818:Animals; D034341:Aristolochic Acids / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D001345:Autoradiography; D001835:Body Weight / Q000187:drug effects; D003404:Creatinine / Q000097:blood / Q000652:urine; D018736:DNA Adducts / Q000032:analysis / Q000187:drug effects; D020372:Dexfenfluramine / Q000008:administration & dosage / Q000633:toxicity*; D004195:Disease Models, Animal; D004357:Drug Synergism; D004365:Drugs, Chinese Herbal / Q000633:toxicity*; D005355:Fibrosis / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology; D007279:Injections, Subcutaneous; D007668:Kidney / Q000737:chemistry / Q000187:drug effects; D008099:Liver / Q000737:chemistry / Q000187:drug effects; D008136:Longevity / Q000187:drug effects; D008297:Male; D009153:Mutagens / Q000008:administration & dosage / Q000378:metabolism / Q000633:toxicity*; D009395:Nephritis, Interstitial / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology*; D010761:Phosphorus Radioisotopes / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000633:toxicity*
D034341:Aristolochic Acids; D018736:DNA Adducts; D004365:Drugs, Chinese Herbal; D009153:Mutagens; D010761:Phosphorus Radioisotopes; D017366:Serotonin Receptor Agonists; C000228:aristolochic acid I; D003404:Creatinine; D020372:Dexfenfluramine